Literature DB >> 18838295

Mode of death in patients with newly diagnosed heart failure in the general population.

Paresh A Mehta1, Simon W Dubrey, Hugh F McIntyre, David M Walker, Suzanna M C Hardman, George C Sutton, Theresa A McDonagh, Martin R Cowie.   

Abstract

BACKGROUND: Early prognosis for incident (new) heart failure (HF) patients in the general population is poor. Clinical trials suggest approximately half of chronic HF patients die suddenly but mode of death for incident HF cases in the general population has not been evaluated. AIMS: To describe mode of death in the first six months after a new diagnosis in the general population.
METHODS: Two-centre UK population-based study.
RESULTS: 396 incident HF patients were prospectively identified. Overall mortality rates were 6% [3-8%], 11% [8-14%] and 14% [11-18%] at 1, 3 and 6months respectively. There were 59 deaths over a median follow-up of 10months; 86% (n = 51) were cardiovascular (CV) deaths. Overall, the mode of death was progressive HF in 52% (n = 31), sudden death (SD) in 22% (n = 13), other CV death in 12% (n = 7), and non-CV death in 14% (n = 8). On multivariable analysis, progressive HF deaths were associated with older age, lower serum sodium, systolic hypotension, prolonged QRS duration at baseline and absence of ACE inhibitor therapy at the time of discharge or death.
CONCLUSION: Early prognosis after a new diagnosis of HF in the general population is poor and progressive HF, rather than sudden death, accounts for the majority of deaths.

Entities:  

Mesh:

Year:  2008        PMID: 18838295     DOI: 10.1016/j.ejheart.2008.09.004

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  8 in total

1.  Possible mechanisms of sudden cardiac death in top athletes: a basic cardiac electrophysiological point of view.

Authors:  András Varró; István Baczkó
Journal:  Pflugers Arch       Date:  2010-02-26       Impact factor: 3.657

2.  Impact of baseline heart failure burden on post-implantable cardioverter-defibrillator mortality among medicare beneficiaries.

Authors:  Chih-Ying Chen; Lynne Warner Stevenson; Garrick C Stewart; John D Seeger; Lauren Williams; Jessica J Jalbert; Soko Setoguchi
Journal:  J Am Coll Cardiol       Date:  2013-03-26       Impact factor: 24.094

Review 3.  Complementary Role of Combined Indirect and Direct Cardiac Sympathetic (Hyper)Activity Assessment in Patients with Heart Failure by Spectral Analysis of Heart Rate Variability and Nuclear Imaging: Possible Application in the Evaluation of Exercise Training Effects.

Authors:  Ferdinando Iellamo; Marco Alfonso Perrone; Andrea Cimini; Giuseppe Caminiti; Agostino Chiaravalloti; Attilio Parisi; Orazio Schillaci
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-05

4.  Angiotensin receptor blocker therapy for heart failure patients: is combination treatment a feasible prospect?

Authors:  P A Mehta; S McDonagh; J Phillips; R Grocott-Mason; S W Dubrey
Journal:  Clin Cardiol       Date:  2009-09       Impact factor: 2.882

5.  Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure.

Authors:  Chih-Ying Chen; Lynne Warner Stevenson; Garrick C Stewart; Deepak L Bhatt; Manisha Desai; John D Seeger; Lauren Williams; Jessica J Jalbert; Soko Setoguchi
Journal:  BMJ       Date:  2015-07-14

6.  Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: cohort study of older patients with heart failure.

Authors:  Soko Setoguchi; Lynne Warner Stevenson; Garrick C Stewart; Deepak L Bhatt; Andrew E Epstein; Manisha Desai; Lauren A Williams; Chih-Ying Chen
Journal:  BMJ       Date:  2014-05-08

Review 7.  Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine.

Authors:  Antonio Carlos Pereira-Barretto
Journal:  Am J Cardiovasc Drugs       Date:  2016-04       Impact factor: 3.571

8.  Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology-A PROLONG-II Substudy.

Authors:  Johanna Mueller-Leisse; Johanna Brunn; Christos Zormpas; Stephan Hohmann; Henrike Aenne Katrin Hillmann; Jörg Eiringhaus; Johann Bauersachs; Christian Veltmann; David Duncker
Journal:  Sensors (Basel)       Date:  2022-03-05       Impact factor: 3.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.